Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
Brief Summary: To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD6244, Drug: Dacarbazine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dacarbazine, Drug: Placebo | Intervention Type: DRUG; Name: AZD6244; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Arm I (sargramostim, peptide vaccine); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Sargramostim, Biological: Tyrosinase Peptide | Arm Label: Arm II (sargramostim placebo, peptide vaccine); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Biological: Tyrosinase Peptide | Arm Label: Arm III (sargramostim, peptide placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Biological: Sargramostim | Arm Label: Arm IV (placebo, peptide placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Arm Label: Arm V (sargramostim); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Sargramostim | Arm Label: Arm VI (sargramostim placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm II (sargramostim placebo, peptide vaccine), Arm III (sargramostim, peptide placebo), Arm IV (placebo, peptide placebo), Arm V (sargramostim), Arm VI (sargramostim placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (sargramostim placebo, peptide vaccine), Arm IV (placebo, peptide placebo), Arm VI (sargramostim placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm III (sargramostim, peptide placebo), Arm IV (placebo, peptide placebo) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm III (sargramostim, peptide placebo), Arm V (sargramostim) | Intervention Type: BIOLOGICAL; Name: Tyrosinase Peptide; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm II (sargramostim placebo, peptide vaccine)
C: Arm Label: Arm A: Ipilimumab and Dacarbazine; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Dacarbazine | Arm Label: Arm B: Placebo and Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Dacarbazine | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm A: Ipilimumab and Dacarbazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm B: Placebo and Dacarbazine | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Arm A: Ipilimumab and Dacarbazine, Arm B: Placebo and Dacarbazine
D: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Drug: vemurafenib | Intervention Type: DRUG; Name: vemurafenib; Assigned to Arm(s): Single arm

Answer: A